Exelixis, Inc. $EXEL Shares Purchased by Citigroup Inc.

Citigroup Inc. lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 48.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 465,031 shares of the biotechnology company's stock after purchasing an additional 152,240 shares during the period. Citigroup Inc. owned about 0.17% of Exelixis worth $17,169,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the business. Deutsche Bank AG grew its stake in Exelixis by 63.8% during the 1st quarter. Deutsche Bank AG now owns 75,820 shares of the biotechnology company's stock valued at $2,799,000 after acquiring an additional 29,531 shares in the last quarter. Ontario Teachers Pension Plan Board grew its stake in Exelixis by 212.8% during the 1st quarter. Ontario Teachers Pension Plan Board now owns 148,726 shares of the biotechnology company's stock valued at $5,491,000 after acquiring an additional 101,181 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Exelixis by 2.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,321,407 shares of the biotechnology company's stock valued at $122,626,000 after acquiring an additional 69,054 shares in the last quarter. Hemington Wealth Management grew its stake in Exelixis by 211.3% during the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 522 shares in the last quarter. Finally, Costello Asset Management INC purchased a new stake in shares of Exelixis in the 1st quarter valued at approximately $39,000. Hedge funds and other institutional investors own 85.27% of the company's stock.

Exelixis Price Performance

Shares of EXEL stock traded down $0.25 during mid-day trading on Monday, hitting $38.07. The stock had a trading volume of 537,583 shares, compared to its average volume of 3,063,610. Exelixis, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $49.62. The firm has a market cap of $10.25 billion, a PE ratio of 18.29, a PEG ratio of 0.80 and a beta of 0.29. The company's 50-day simple moving average is $41.96 and its 200-day simple moving average is $39.20.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its earnings results on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company had revenue of $568.26 million during the quarter, compared to analysts' expectations of $574.36 million. During the same quarter last year, the business earned $0.84 EPS. The business's revenue was down 10.8% on a year-over-year basis. On average, analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Insider Activity

In other news, EVP Patrick J. Haley sold 34,387 shares of the firm's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $44.06, for a total value of $1,515,091.22. Following the completion of the sale, the executive vice president owned 412,072 shares in the company, valued at approximately $18,155,892.32. This trade represents a 7.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jack L. Wyszomierski sold 7,535 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total transaction of $324,683.15. Following the completion of the sale, the director owned 358,882 shares of the company's stock, valued at $15,464,225.38. This trade represents a 2.06% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 65,304 shares of company stock worth $2,846,164 over the last quarter. Insiders own 2.85% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on EXEL shares. UBS Group set a $38.00 price target on shares of Exelixis and gave the company a "neutral" rating in a research note on Wednesday, July 30th. Stephens raised shares of Exelixis from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $29.00 to $60.00 in a research note on Tuesday, June 24th. Jefferies Financial Group set a $50.00 price target on shares of Exelixis and gave the company a "buy" rating in a research note on Tuesday, June 24th. Citigroup increased their price target on shares of Exelixis from $45.00 to $56.00 and gave the company a "buy" rating in a research note on Thursday, May 15th. Finally, Royal Bank Of Canada dropped their price target on shares of Exelixis from $50.00 to $45.00 and set a "sector perform" rating for the company in a research note on Tuesday, July 29th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Exelixis currently has a consensus rating of "Moderate Buy" and an average target price of $44.06.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.